HEARTSEED RAISES $26M IN SERIES B FUNDING.

 
FREE EXCERPT

Heartseed (Heartseed Inc.) has raised 2.8 Billion-yen (approx. $26 Million) at Series B round, bringing its total financial backing to 3.8 Billion yen (approx. $35 Million) since it was founded in 2015.

Participants in the Series B included new investors, SBI Investment, JMDC, Gene Techno Science, Nissay Capital, SMBC Capital, and an existing investor, Astellas Venture Management LLC., which has supported Heartseed from Series A.

I have been involved in the research of cardiac regenerative medicine for the past 20-years as a pioneer in this field and solved all the major challenges such as ventricular-specific cardiomyocyte differentiation, purification, large-scale manufacturing and efficient cell delivery, said Prof. Keiichi Fukuda, co-founder and CEO at Heartseed, Professor at the Department of Cardiology, Keio University, Tokyo. We are grateful for the support of our investors, which I believe is a reflection of their expectation and confidence that our lead pipeline HS-001 can be a curative therapy for severe HF, with the mechanism that transplanted ventricular-specific highly-purified cardiomyocytes engraft...

To continue reading

FREE SIGN UP